FABRE-KRAMER PHARMACEUTICALS, INC

Lobbying Spend

—

Filings

Firms Hired

Active Period

2015–2016

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2016	—	4	1
2015	—	3	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
COVINGTON & BURLING LLP	—	7

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	4
SENATE	4

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	5

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6114th Congress

21st Century Cures Act

2015 · fourth_quarter · Firm: COVINGTON & BURLING LLP

Cited source text and reported amounts

Policy regarding demonstration of effectiveness for new drug approvals. 21st Century Cures (HR 6); No Senate Bill number yet

Client expense: — · Firm income: $15,000

Matched citations: HR 6

H.R. 6114th Congress

21st Century Cures Act

2015 · third_quarter · Firm: COVINGTON & BURLING LLP

Cited source text and reported amounts

Policy regarding demonstration of effectiveness for new drug approvals. 21st Century Cures (HR 6); No Senate Bill number yet

Client expense: — · Firm income: $20,000

Matched citations: HR 6

FABRE-KRAMER PHARMACEUTICALS, INC — Lobbying Disclosure | Poliscope